Current trends in the treatment of hypertension: A mixed picture

American Journal of Hypertension

Volumn 10, Issue 12 II SUPPL., 1997, Pages

  Julius, Stevo ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiotensin II receptor antagonist; Drug therapy; Hypertension; Morbidity; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; PLACEBO; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; DRUG EFFECT; HUMAN; HYPERTENSION; MORBIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0031409577     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00389-0     Document Type: Article

References (37)

1. Effects of treatment on morbidity in hypertension results in patients with diastolic blood pressure averaging 90 through 114 mmHg . JAMA. 213:1970;1143-1152.
2. Mulrow CD, Cornell JA, Herrera CR, et al. Hypertension in the elderly Implications and generalizability of randomized trials . JAMA. 272:(24):1994;1932-1938.
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease Part 2. Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context . Lancet. 335:1990;827-838.
4. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population Results from the Third National Health and Nutrition Examination Study . Hypertension. 25:1995;305-313.
5. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult U.S. population Data from the Health Examination Surveys, 1960 to 1961 . Hypertension. 26:1995;60-69.
6. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. JAMA. 259:1988;3579-3586.
7. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia A link between hypertension obesity and glucose intolerance . J Clin Invest. 75:1985;809-817.
8. Berglund G, Larsson B, Andersson O, et al. Body composition and glucose metabolism in hypertensive middle-aged males. Acta Med Scand. 200:1976;163-169.
9. Reaven GM. Banting lecture 1988; role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
10. Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk Tecumseh Blood Pressure Study . JAMA. 264:1990;354-358.
11. Smith SD, Julius S, Jamerson K, et al. Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. Hypertension. 12:1994;455-462.
12. Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 19:1980;205-210.
13. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:1979;154-160.
14. Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as a coronary heart disease risk factor relationship to other risk factors and predictive value during 9 1 2 year follow-up of the Helsinki Policemen Study population . Acta Med Scand. 701:(suppl):1985;38-52.
15. Sorlie PD, Garcia-Palmieri MR, Costas R Jr, et al. Hematocrit and risk of coronary heart disease the Puerto Rico Heart Health Program . Am Heart J. 101:1981;456-461.
16. Campbell MJ, Elwood PC, Mackean J, et al. Mortality, haemoglobin level and haematocrit in women. J Chronic Dis. 38:1985;881-889.
17. Julius S, Gudbrandsson T, Jamerson K, et al. Hypothesis The hemodynamic link between insulin resistance and hypertension . J Hypertens. 9:1991;983-986.
18. Julius S. Sympathetic hyperactivity and coronary risk in hypertension (Corcoran Lecture). Hypertension. 21:1993;886-893.
19. Esler M, Julius S, Sweifler A, et al. Mild high-renin essential hypertension neurogenic human hypertension? N Engl J Med. 296:1977;405-411.
20. Julius S, Krause L, Schork K, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 9:1991;77-84.
21. Alderman MH, Madhavan S, Oot WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 324:1991;1098-1104.
22. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 15:1997;1-15.
23. Dzau VJ. Short- and long-term determinants of cardiovascular function and therapy contributions of circulating and tissue renin-antiotensin systems . J Cardiovasc Pharmacol. 14:(suppl 4):1989;S1-S5.
24. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 18:(suppl):1991;II-100-II-105.
25. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest. 72:1983;732-738.
26. Hart MN, Heistad DD, Brody MJ. Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels. Hypertension. 2:1980;419-428.
27. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 322:1990;1561-1566.
28. Folkow B. Role of vascular factors in hypertension. Contrib Nephrol. 8:1977;81-94.
29. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
30. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 153:1993;159-183.
31. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. March:1987;581-584.
32. Alderman MH, Madhavan S, Cohen H. Antihypertensive drug therapy The effect of JNC criteria on prescribing patterns and patient status through the first year . Am J Hypertens. 9:1996;413-418.
33. Julius S. The evidence for a pathophysiology significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens [A]. 18:1996;305-321.
34. The Australian therapeutic trial in mild hypertension. Lancet. 1:1980;1261-1267.
35. Untreated mild hypertension. Lancet. i:1982;185-191.
36. Julius S, Schork MA: Predictors of hypertension, in Perry HM, Jr, Smith WM (eds): Mild Hypertension: To Treat or Not to Treat. Annals of the New York Academy of Sciences, Vol. 304. NY Academy of Sciences, New York, 1978, pp. 38-52.
37. Five-year findings of the hypertension detection and follow-up program I. Reduction in mortality of persons with high blood pressure, including mild hypertension . JAMA. 242:1979;2562-2571.